A BioPhorum member survey examining approaches taken for labelling of allogeneic CGT clinical drug product.
Benchmarking
Viewing related articles
PAT and Rapid Analytics supporting rapid manufacture survey
May 2023 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, PAT Monitoring and Control, POI - Cell and Gene Therapy
A BioPhorum member only benchmarking survey focusing on enabling rapid manufacture.
Supply chain constraints benchmarking survey
Apr 2023 | Benchmarking, Deliverable, Deliverables Report, POI - Supply Chain to Patient, Supply Chain to Patient
This BioPhorum member only survey explores the challenges of the internal supply chain and the impact they are having on the business. One key theme that appeared to be emerging is that internal resource is a constraint within the supply chain for many companies.
Viral clearance paper implementation tracking survey results 2022
Apr 2023 | Benchmarking, Deliverable, Deliverables Report, Development Group, POI - Development Group, Viral Clearance
For the last three years, the BioPhorum Viral Clearance team have completed a short survey on their published papers to understand how they have been used and the response of regulators if used to support filings. This is the report for 2022
Survey to evaluate the current use of PAT software for chemometrics and PAT infrastructure
Apr 2023 | Benchmarking, Deliverable, Deliverables Report, Development Group, PAT Monitoring and Control, POI - Development Group
A BioPhorum member only survey that aims to tackle questions around the types of PAT software for chemometrics and PAT infrastructure used, ease of instalment, its advantages and limitations
AAV Bioreactor scale-up bench-marking survey
Dec 2022 | Benchmarking, Cell & Gene Therapy, Commercialization, Deliverable, Deliverables Report
A BioPhorum member only survey to help gain further insight around how the industry is approaching scaling the production of AAV in suspension HEK- 293 cells from lab to commercial scale.
Characterization and risk assessment of host cell proteins using mass spectrometry
Nov 2022 | Benchmarking, Deliverable, Deliverables Report, Development Group, Host Cell Proteins and other Bioresidual Impurities
A BioPhorum member survey to gather preliminary information from across the biopharmaceutical industry on the characterization and risk assessment of HCP using mass spectrometry.
Enzymatic activity assays – general usage assessment
Nov 2022 | Benchmarking, Deliverable, Deliverables Report, Development Group, Host Cell Proteins and other Bioresidual Impurities
A BioPhorum member only survey to share knowledge into how, why and when enzymatic activity assays are performed.
Sampling strategy to test for presence of mycoplasma in cell therapies
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, High Level Analytics
BioPhorum member only benchmarking exercise seeking member experience on expectations for mycoplasma testing of cell therapies.
Empty/full Capsids (AAV / LVV) testing strategies
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, High Level Analytics
BioPhorum member benchmarking survey on testing strategies for AAV and LVV empty, full and partially filled capsids.